NCT03047811Unknown不适用
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
适应症
干预措施
试验速览
- 阶段
- 不适用
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- overall survival (OS)
研究概览
简要总结
The study of targeted NY-ESO-1 T cell receptor (TCR) genetic modified autologous T cells treatment of advanced solid tumors
- The main purpose - security and ORR;
- A secondary purpose - median progression-free surial;1 year, 2 years, total 5 years survival rate;The quality of life.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •3.1.1 volunteered for the clinical research and signed informed consent. 3.1.2 aged 18-70, expected lifetime > 3 months. 3.1.3 gender not limited. 3.1.4 late lung cancer (stage IIIb/IV), (IV) with esophageal carcinoma, and melanoma (advanced), no other effective cure Treatment method can be selected patients. 3.1.5 biopsy IHC confirmed positive expression, NY - ESO - 1 or 50% of the tumor cells IHC staining in 2 + and/or 3 +.Organization based on time in the group in the year before, can be a tumor tissue, can also be a pleural effusion cells
排除标准
- •3.2.1 this study used in the process of cell preparation ingredients allergy, such as penicillin, streptomycin.
- •3.2.2 used within a week of tyrosine kinase inhibitors (the treatment such as, for it), or other cancer drugs.
- •3.2.3 is systemic anti-cancer therapy, including immune therapy, such as accept the immune cells within a month back to lose Therapy or biological treatment.6 weeks used cancer associated with tumor immune single resistance (including the PD, PD - L1 and - 1 CTLA 4 single resistance). 3.2.4 have vital organs, such as cardiovascular, respiratory system disease, myocardial infarction, myocardial ischemia, the coronary artery bypass History or coronary ischemia symptoms, obstructive or restrictive lung disease. 3.2.5 the patient's immune tolerance is poor, may on the immune cells in treatment of the reaction of low or prone to toxic reactions.
- •3.2.6 always have autoimmune and immunodeficiency disease. 3.2.7 radiation pneumonitis. 3.2.8 depends on oxygen. 3.2.9 four weeks into the set of other therapeutic studies or clinical trials. 3.2.10 used experimental vaccine in two months 3.2.11 systemic corticosteroids used within two weeks, hydroxyurea or immune inhibitors (such as IL - 2, Interferons alpha, IFN - gamma, GSF, mTOR inhibitors, ring spore element, etc.).Recently or are using suction The sex hormone. 3.2.12 year have chronic or recurrent severe autoimmune diseases. 3.2.13 uncontrolled active infection. 3.2.14 2-4 acute or persistent during graft versus host disease (GVHD). 3.2.15 serious heart disease, after treatment of the disease is still unstable, into the group of the first six months after myocardial infarction, and congestion Heart failure, unstable angina, symptoms of pericardial effusion or unstable arrhythmia.
- •3.2.18 always suffer from other cancers, but does not include: A. basal cell carcinoma and squamous cell carcinoma after active treatment, the wound healed completely.
- •B. the cervical or breast carcinoma in situ cure for at least three years. C. primary malignant tumors were removed completely, completely relieve five years or more.
- •3.2.19 accompanied by primary or secondary brain tumor patients. 3.2.20 the mentally disabled. 3.2.21 doubt or have alcohol and drug abuse history. 3.2.22 physicians determine cannot or may not be able to complete the test subjects.
- •3.2.23 any not listed may interfere with the patient to participate in the active disease.
研究组 & 干预措施
TCR - T cell therapy
Experimental
Peripheral blood mononuclear cells collected: draw 100-150 ml of peripheral blood in patients and separate of the peripheral blood mononuclear cells, the total number of cells 1.5 * 10 ^ 7 / kg - 1 * 10 ^ 8 / kg Fludarabine 25 mg/m2 + NS 250 ml, ivgtt qdx5d, CTX 60 mg/kg + NS 250 ml, ivgtt qd x2d, should be in front of the TCR - T cells infusion of 4 days reinfusion the total number of T cells （1* 10 ^ 8 / kg - 10 * 10 ^ 8 / kg） in 3 days , infusion 10-15 minutes, should not be more than 20 minutes.
干预措施: TCR - T cell therapy (Other)
结局指标
主要结局
overall survival (OS)
时间窗: From date of randomization until the date of date of death from any cause, whichever came first, assessed up to 36 months
次要结局
未报告次要终点
研究者
Xianghua Wu
Clinical Associate Professor
Fudan University
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing MalignanciesEsophagus CarcinomaBladder CarcinomaOther Metastatic Solid CancersSynovial SarcomaNeuroblastomaBreast CancerLung CancerMultiple MyelomaOvarian CancerMelanomaNCT02457650Shenzhen Second People's Hospital36
终止
2 期
NY-ESO-1 T Cells in OG CancerOesophageal CancerNCT01795976Fiona Thistlethwaite2
撤回
1 期
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple MyelomaRefractory Plasma Cell MyelomaHLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Plasma Cell MyelomaNCT03506802Jonsson Comprehensive Cancer Center
终止
1 期
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced CancerLocally Advanced Malignant NeoplasmNY-ESO-1 PositiveHLA-A*0201 Positive Cells PresentUnresectable Malignant NeoplasmSarcomaNCT03240861Jonsson Comprehensive Cancer Center5
已完成
1 期
Multi-center Phase I/II Study of NY-ESO-1 T Cell Receptor Gene Transferred T Lymphocytes in Patients With Synovial SarcomaSynovial sarcomaJPRN-jRCT1080223459Takara Bio Inc.8